Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: A novel nanobody-heavy chain antibody against Angiopoietin-like protein 3 reduces plasma lipids and relieves nonalcoholic fatty liver disease

Fig. 2

The affinity test of anti-hANGPTL3-CCD VHHs and epitope binning assay. a Identification of ANGPTL3 specific VHHs from 48 clones specifically binding with hANGPTL3 after three rounds bio-panning. b The SDS-PAGE analysis of the C27-His6, C44-His6 and C46-His6. M: Maker; lane 1: C27-His6; lane 2: C44-His6; lane 3: C46-His6. c–e The affinity of C27-His6, C44-His6 and C46-His6 binding to hANGPTL3 (S17-P220)-His6. f The assay for hANGPTL3-binding epitopes of the C44-His6 was performed against evinacumab by the dual antibody sandwich ELISA. The horizontal and vertical axes represent the concentrations of the C44-His6 and the OD450 value

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us